Day 2. Saturday, 27 September 2025,

8am to 7pm

Session 4 - Moderators: Dr. Asma El Hassan , Dr. Ashraf Awadelkarim

7.30am to 7.55am

Registration

7.55am to 8am

Day 2 Opening Remarks

8am to 8.15am

Melanoma/Skin Cancers (Abstract 9506) DREAMseq: A phase III trial of treatment sequences in BRAFV600-mutant (m) metastatic melanoma (MM) - Final clinical results

Dr. Asma El Hassan

Senior Consultant Medical Oncologist, NCCCR

8.15am to 8.30am

Melanoma/Skin Cancers(Abstract LBA9507) A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000 (NCT04511013)

Dr. Ashraf Awadelkarim

Associate Consultant Medical Oncologist, NCCCR

8.30am to 8.45am

Melanoma/Skin Cancers (Abstract 9515) Lifileucel in patients with advanced melanoma: 5-year outcomes of the C-144-01 study

Dr. Mutie Ullah Ahmed

Clinical Fellow, Oncologist, NCCCR

8.45am to 9am

Melanoma/Skin Cancers(Abstract LBA9508) Comparison of 1 year versus minimum 2 years of anti-PD1-based immunotherapy as first line treatment for metastatic melanoma: Results of the DANTE phase III trial

Dr. Mohamed Aboagla

Specialist, Oncologist, NCCCR

9am to 9.15am

Symptom Science and Palliative Care (Abstract12003) Music therapy versus cognitive behavioral therapy for anxiety in cancer survivors: A telehealth-based randomized clinical trial

Dr. Abdelhamid Afana

Senior Clinical Psychologist, NCCCR

9.15am to 9.35am

Coffee Break

9.35am to 9.50am

Quality Care/Health Services Research (Abstract 11001) Outcomes of an electronic patient-reported outcomes (ePRO)–based symptom management program (eSyM): A cluster randomized trial

Ms. Wafaa Shehada

Clinical Nurse Specialist, NCCCR

9.50am to 10.05am

Quality Care/Health Services Research (Abstract 11003) Randomized trial of a supportive oncology care at home intervention for patients with cancer receiving curative treatment

Ms. Asma Younus

Clinical Nurse Specialist, NCCCR

10.05am to 10.20am

Quality Care/Health Services Research (Abstract 11021) Are patients satisfied with the information in an informed consent form? Questionnaire-based study examining patients' viewpoints

Dr. Mokhtar Ghoul

Clinical Research Specialist, NCCCR

10.20am to 10.35am

Quality Care/Health Services Research (Abstract 11005) Real-world social determinants of health (SDOH) and outcomes of early-onset colorectal cancer (EO-CRC): An analysis of a large, nationally representative US community oncology network

Dr. Hadi Mohamad Abu Rasheed

Head of the Cancer Awareness and Professional Development Department, Qatar Cancer Society

10.35am to 10.50am

PANEL DISCUSSION

Session 5 - Moderators: Dr. Hind El Malik, Dr. Mohammed Ussama Al Homsi

10.50am to 11.05am

Gynecologic Cancer (Abstract LBA5504) Pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer: Final analysis results of the phase 3, randomized, double-blind ENGOT-cx11/GOG-3047/KEYNOTE-A18 study

Dr. Hind El Malik

Senior Consultant Medical Oncologist, NCCCR

11.05am to 11.20am

Gynecologic Cancer (Abstract 5515) A phase II trial of pembrolizumab and lenvatinib in recurrent or persistent clear cell ovarian carcinoma (NCT05296512)

Dr. Cicy Mary Jacob

Consultant Medical Oncologist, NCCCR

11.20am to 11:35am

Gynecologic Cancer (Abstract 5511) Primary results of a phase 2 study of cisplatin-sensitized radiation therapy and pembrolizumab for unresectable vulvar cancer

Dr. Suparna Chandramouli

Associate Consultant Radiation Oncologist, NCCCR

11:35am to 11:50am

Genitourinary Cancer - Kidney and Bladder (Abstract 4500) Nivolumab plus ipilimumab (NIVO+IPI) vs gemcitabine-carboplatin (gem-carbo) chemotherapy for previously untreated unresectable or metastatic urothelial carcinoma (mUC): Final results for cisplatin-ineligible patients from the CheckMate 901 trial

Dr. Mohammed Ussama Al Homsi

Conference Chairman

Deputy Medical Director for Research and Medical Education, Senior Consultant Medical Oncologist, NCCCR

11:50am to 12:05pm

Genitourinary Cancer - Prostate, Testicular, and Penile (Abstract LBA5006) Phase 3 AMPLITUDE trial: Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes

Dr. Israa Amr Elhakeem

Clinical Fellow, Oncologist, NCCCR

12:05pm to 12.20pm

PANEL DISCUSSION

12.20pm to 1.20pm

Prayer & Lunch Break

Session 6 - Moderators: Dr. Anas Hamad, Dr. Reyad Mohsen, Dr. Said Dermime

1:20pm to 1:35pm

Care Delivery/Models of Care (Abstract 1501) Remote clinical pharmacist impact on reducing total cost of care in Enhancing Oncology Model–enrolled oncology practices

Dr. Sahar Nasser

Clinical Pharmacist, NCCCR

1.35pm to 1.50pm

Developmental Therapeutics - Immunotherapy (Abstract 2511) Safety and efficacy of immune checkpoint inhibitors in solid organ transplant recipients: A systematic review and individual patient data meta-analysis

Dr. Anas Hamad

Director of Pharmacy Department, NCCCR

1.50pm to 2.05pm

Developmental Therapeutics - Immunotherapy (Abstract 2501) First-in-human phase I/II trial evaluating BNT142, a first-in-class mRNA encoded, bispecific antibody targeting Claudin 6 (CLDN6) and CD3, in patients (pts) with CLDN6-positive advanced solid tumors

Dr. Said Dermime

Director for Cancer Translational Research Facility, NCCCR

2.05pm to 2.20pm

Lung Cancer - Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers (Abstract 8006) Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Primary results of the phase 3 IMforte trial

Dr. Reyad Mohsen

Senior Consultant Medical Oncologist, NCCCR

2.20pm to 2.35pm

Lung Cancer - Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers (Abstract LBA8000) Overall survival with neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) in patients with resectable NSCLC in CheckMate 816

Dr. Ammar Madani

Associate Consultant Medical Oncologist, NCCCR

2.35pm to 2.50pm

Lung Cancer - Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers (Abstract 8001) Neoadjuvant (neoadj) osimertinib (osi) ± chemotherapy (CT) vs CT alone in resectable (R) epidermal growth factor receptor-mutated (EGFRm) NSCLC: NeoADAURA

Dr. Hassan Aakel

Specialist, Medical Oncologist, NCCCR

2.50pm to 3.05pm

Lung Cancer - Non-Small Cell Metastatic (Abstract 8506) Patritumab deruxtecan (HER3-DXd) in resistant EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) after a third-generation EGFR TKI: The phase 3 HERTHENA-Lung02 study

Dr. Muhammed Hajmusa

Clinical Fellow, Oncologist, NCCCR

3.05pm to 3.20pm

Lung Cancer - Non-Small Cell Metastatic (Abstract 8503) Efficacy of zipalertinib in NSCLC patients with EGFR exon 20 insertion mutations who received prior platinum-based chemotherapy with or without amivantamab

Dr. Majd Aldwairi

Clinical Fellow, Oncologist, NCCCR

3.20pm to 3.35pm

PANEL DISCUSSION

3.35pm to 3.55pm

Prayer & Coffee Break

Session 7 - Moderators: Dr. Azza Hassan, Dr. Abdulrehman Zar Gul, Dr. Aladdin Kanbour 

3.55pm to 4.10pm

Symptom Science and Palliative Care (Abstract12001) Phase III randomized placebo-controlled trial on repurposing olanzapine for prevention of radiotherapy-induced nausea and vomiting (RINV): CTRI/2022/01/039723

Dr. Iman AlDiri

Pain & palliative care consultant, Kuwait Cancer Control Center, Kuwait

4.10pm to 4.25pm

Symptom Science and Palliative Care (Abstract LBA12000) PRO-ACTIVE: Results of a pragmatic phase IV randomized trial comparing the effectiveness of prophylactic swallow intervention for patients receiving radiotherapy for head and neck cancer

Dr. Alaa Mamoun Khalafalla

Palliative Care Specialist, NCCCR

4.25pm to 4.40pm

Symptom Science and Palliative Care (Abstract 12006) A multicenter, randomized, controlled, open-label trial to determine the optimal duration of steroid therapy for mild pneumonitis associated with immune checkpoint inhibitors

Dr. Sair Ibrahim

Palliative Care Specialist, NCCCR

4.40pm to 4.55pm

Symptom Science and Palliative Care (Abstract 12007) Romiplostim for chemotherapy‑induced thrombocytopenia (CIT) in colorectal, gastroesophageal, and pancreatic cancers: A global, phase 3, randomized, placebo-controlled trial (RCT)

Dr. Rawan Dawoud

Clinical Pharmacy Specialist, NCCCR

4.55pm to 5.10pm

Head & Neck (Abstract 6012) Neoadjuvant and adjuvant pembrolizumab plus standard of care (SOC) in resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC): Exploratory efficacy analyses of the phase 3 KEYNOTE-689 study

Dr. Abdulrehman Zar Gul

Senior Consultant Medical Oncologist, NCCCR

5.10pm to 5.25 pm

Head & Neck (Abstract LBA6003) PD-1 blockade with toripalimab incorporated into induction chemotherapy and radiotherapy with or without concurrent cisplatin in locoregionally advanced nasopharyngeal carcinoma (DIAMOND): A multicenter, non-inferiority, phase 3, randomized controlled trial

Dr. Aladdin Kanbour

Consultant Medical Oncologist, NCCCR

5.25pm to 5.40pm

PANEL DISCUSSION

5.40pm to 6.00pm

Prayer

6pm to 7pm

Closing Ceremony

Dr. Mohammed Ussama Al Homsi

Conference Chairman

Deputy Medical Director for Research and Medical Education, Senior Consultant Medical Oncologist, NCCCR

Dr. Anas Hamad

Chairman of Organizing Committee

Director of Pharmacy Dept, NCCCR